IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9932317 B1

PDFFull Text
Date of Patent:
Apr. 03, 2018

Filed:

Mar. 19, 2013

Quinazoline compounds and their use in therapy

Applicants:

Imperial Innovations Limited, London, GB;

Emory University, Atlanta, GA (US);

Inventors:

Robert Brown, London, GB;

Matthew John Fuchter, London, GB;

Nadine Chapman-Rothe, London, GB;

Nitipol Srimongkolpithak, London, GB;

Joachim Caron, London, GB;

James Snyder, Atlanta, GA (US);

Thota Ganesh, Atlanta, GA (US);

Jin Liu, Atlanta, GA (US);

Aiming Sun, Atlanta, GA (US);

Assignees:

Imperial Innovations Limited, London, GB;

Emory University, Atlanta, GA (US);

Attorney:

Kilyk & Bowersox, P.L.L.C.

Primary Examiner:

Emily Bernhardt

Int. Cl.
CPC ...
C07D 401/12 (2006.01); C07D 401/14 (2006.01); A61K 31/517 (2006.01); C07D 239/95 (2006.01); C07D 405/14 (2006.01); C07D 491/056 (2006.01); C07D 403/12 (2006.01); C07D 401/04 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 31/55 (2006.01); A61K 31/551 (2006.01);
U.S. Cl.
CPC ...
C07D 239/95 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/55 (2013.01); A61K 31/551 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 405/14 (2013.01); C07D 491/056 (2013.01);
Abstract

This invention relates to quinazoline compounds of Formula (I) which are inhibitors of the histone lysine methyltransferase (HKMTase) EZH2, and to uses of such compounds as medicaments, in particular in the treatment of a disease or disorder in which inhibition of EZH2 provides a therapeutic or prophylactic effect.

Find Patent Forward Citations

Loading…